



Living Cell Technologies Limited

CAN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Safety and efficacy findings of DIA-09 study of DIABECCELL for type 1 diabetes

31 October 2013 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced the findings of DIA-09 - a Phase I/IIa clinical trial of DIABECCELL® in patients with type 1 diabetes.

The non-randomised, open label, study was conducted at the Hospital Eva Perón, Buenos Aires, Argentina by Principal Investigator - Dr. Adrián G. Abalovich.

The trial involved eight patients split into two groups of four. Group one received two 5,000 IEQ/kg doses of DIABECCELL (islet equivalents per kilogram of body weight). Group two received two 10,000 IEQ/kg doses of DIABECCELL. In both groups, the second dose was implanted 12 weeks after the first. Endpoints were assessed 52 weeks after the second implant.

The main findings one year after the second implant are:

- Overall unaware hypoglycaemic events (UHE) were reduced by 57%. All patients (4/4) in the higher dose group reduced UHE by >40% without an increase in HbA1c and 3 of 4 patients in the lower dose group reduced UHE by >30% without an increase in HbA1c.
- HbA1c fell 1.5-2% in the group receiving the bigger dose and 3 of 4 patients in this group maintained HbA1c of <7%
- The average daily insulin dose was reduced in 7/8 patients.
- Modified Ryan scores indicating the frequency and severity of hypoglycaemic events were significantly reduced in the higher dose group

Analyses are underway to measure levels of porcine insulin and pro-insulin in recipients and correlate these with the clinical improvements observed.

All participants had minor side effects from the implantation of DIABECCELL, such as abdominal pain and fever, and these quickly resolved. One recipient had a severe adverse event from the implantation, namely lack of bowel movement, and this settled with intravenous medication.

Managing Director, Andrea Grant says, "Just as one would hope for with a Phase I/IIa study, these results provide invaluable safety and efficacy data as the basis for further improvements in the product and its method of administration. As previously announced, recent research and development work performed by Diatranz Otsuka Limited (DOL) indicates that there is a genuine opportunity to develop an improved formulation of DIABECCELL and a revised regulatory pathway for this improved formulation is currently in preparation"

The results have been accepted for presentation at the 12th Congress of the International Xenotransplantation Society being held in Osaka, 10th – 13th November, 2013.

– Ends –

For personal use only

For further information: www.lctglobal.com

At the company:

Dr Andrea Grant
Managing Director
Tel: +64 9 270 7941
Mobile: +64 21 078 5421
agrant@lctglobal.com

Media enquires – NZ:

Rachael Joel
Botica Butler Raudon Partners
Tel: +64 9 303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz

Media enquiries – Australia & World

Shevaun Cooper
Buchan Consulting
Tel: +61 3 9866 4722
Mobile: +61 421 760 775
scooper@buchanwe.com.au

About DIABECCELL

Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.

Treatment with DIABECCELL™ involves transplanting pig pancreatic islet cells into a patient's abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.

DIABECCELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECCELL®, for the treatment of Type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease.

Through an innovative joint venture, Diatranz Otsuka Limited (DOL) with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECCELL and the Phase I clinical trials of NTCELL in Parkinson's disease. LCT retains a 50% share of future profits from DIABECCELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT's unique, proprietary technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For personal use only

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

For personal use only